Abstract
Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity.
| Original language | English |
|---|---|
| Pages (from-to) | 4121-4125 |
| Number of pages | 5 |
| Journal | Human Vaccines and Immunotherapeutics |
| Volume | 17 |
| Issue number | 11 |
| DOIs | |
| State | Published - 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- COVID-19
- SARS-CoV-2
- antibodies
- antibody-dependent enhancement
- neutralization
- spike protein
- vaccine
Funding Agency
- Kuwait Foundation for the Advancement of Sciences
Fingerprint
Dive into the research topics of 'Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver